Results 11 to 20 of about 17,217,890 (291)

Non-Clear Cell Renal Cell Carcinoma: Current Management and Best Practice

Kidney Cancer, 2017
The treatment of metastatic renal cell carcinoma (mRCC) has evolved markedly over the past several decades; first with the introduction of targeted therapies and more recently with data supporting checkpoint inhibition.
Meghan Salgia, Jacob Adashek, Paulo Bergerot, Sumanta K. Pal   +3 more
doaj   +4 more sources

Therapeutic approaches in clear cell and non-clear cell renal cell carcinoma

Acta Clinica Belgica, 2016
Renal cell carcinoma (RCC) accounts for 2.4% of all malignancies worldwide diagnosed with 338,000 estimated new cases globally in 2012. In the last decade, the therapeutic landscape for RCC patients has changed tremendously. In this review, we will summarize the treatment options currently available for clear-cell localized, advanced and metastatic RCC
T, Vermassen, A, De Meulenaere, M, Van de Walle, Sylvie, Rottey   +3 more
openaire   +3 more sources

Molecular Characterization of m6A Modifications in Non-Clear Cell Renal Cell Carcinoma and Potential Relationship with Pathological Types [PDF]

International Journal of General Medicine, 2022
Xuebao Xiang, Yi Guo, Zhongyuan Chen, Zengnan Mo Center for Genomic and Personalized Medicine, Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical ...
Xiang X, Guo Y, Chen Z, Mo Z
doaj   +2 more sources

Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma [PDF]

Journal for ImmunoTherapy of Cancer, 2018
Background Nivolumab is approved for patients with metastatic renal cell carcinoma (mRCC) refractory to prior antiangiogenic therapy. The clinical activity of nivolumab in patients with non-clear cell RCC subtypes remains unknown as these patients were ...
Vadim S. Koshkin, Pedro C. Barata, Tian Zhang, Daniel J. George, Michael B. Atkins, William J. Kelly, Nicholas J. Vogelzang, Sumanta K. Pal, JoAnn Hsu, Leonard J. Appleman, Moshe C. Ornstein, Timothy Gilligan, Petros Grivas, Jorge A. Garcia, Brian I. Rini   +14 more
doaj   +3 more sources

Characteristics and Treatment Challenges of Non-Clear Cell Renal Cell Carcinoma. [PDF]

Cancers (Basel), 2021
Non-clear cell renal cell carcinomas (RCC) comprise several rare and poorly described diseases, often characterized by bad prognosis and with no standard treatments available. The gap in their clinical management is linked to the poor molecular characterization in handling the treatment of non clear-cell RCC with untailored therapies.
Sepe P, Ottini A, Pircher CC, Franza A, Claps M, Guadalupi V, Verzoni E, Procopio G.   +7 more
europepmc   +4 more sources

Genetics and Tumor Microenvironment of Renal Cell Carcinoma

Société Internationale d’Urologie Journal, 2022
Renal cell carcinoma is a diverse group of diseases that can be distinguished by distinct histopathologic and genomic features. In this comprehensive review, we highlight recent advancements in our understanding of the genetic and microenvironmental ...
Sari Khaleel, Christopher Ricketts, W. Marston Linehan, Mark Ball, Brandon Manley, Samra Turajilic, James Brugarolas, Ari Hakimi   +7 more
doaj   +1 more source

Genomic profiles of renal cell carcinoma in a small Chinese cohort

Frontiers in Oncology, 2023
ObjectivesOur aim was to describe the molecular characteristics of Renal Cell Carcinoma (RCC) and develop a small panel of RCC-associated genes from a large panel of cancer-related genes.Materials and methodsClinical data of 55 patients with RCC ...
Sheng Tai, Sheng Tai, Sheng Tai, Dan-dan Xu, Dan-dan Xu, Zhixian Yu, Yu Guan, Yu Guan, Shuiping Yin, Shuiping Yin, Shuiping Yin, Jun Xiao, Song Xue, Chaozhao Liang, Chaozhao Liang, Chaozhao Liang   +15 more
doaj   +1 more source

Targeted therapies for non-clear renal cell carcinoma [PDF]

Targeted Oncology, 2010
The treatment of advanced and metastatic kidney cancer has been revolutionized by the development of targeted systemic therapies. Despite the growing number of available agents approved for use against clear cell renal cell carcinoma, patients with non-clear histologies, constituting approximately 1 in 4 cases of kidney cancer, have not received the ...
Eric A, Singer, Gennady, Bratslavsky, W Marston, Linehan, Ramaprasad, Srinivasan   +3 more
openaire   +2 more sources

Systematic Review of Treatment of Metastatic Non-Clear Cell Renal Cell Carcinoma

Kidney Cancer, 2022
BACKGROUND: Metastatic and unresectable non-clear cell renal cell carcinoma comprises more than a quarter of kidney cancers but does not have standardized treatment.
Jason R. Brown, Adam Calaway, Erik Castle, Jorge Garcia, Pedro C. Barata   +4 more
doaj   +1 more source

Chromosome 9p deletion in clear cell renal cell carcinoma predicts recurrence and survival following surgery [PDF]

, 2014
Background:Wider clinical applications of 9p status in clear cell renal cell carcinoma (ccRCC) are limited owing to the lack of validation and consensus for interphase fluorescent in situ hybridisation (I-FISH) scoring technique.
Fleming, S., P Rauchhaus, J Fitzpatrick, Fitzpatrick, J., N Pratt, S Fleming, J Bondad, J Cunningham, El-Mokadem, I., Cunningham, J., Bondad, J., Nabi, G., Rauchhaus, P., G Nabi, Pratt, N., I El-Mokadem   +15 more
core   +1 more source